Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
XFOR
vs
S&P 500
XFOR
S&P 500
Over the past 12 months, XFOR has underperformed S&P 500, delivering a return of -17% compared to S&P 500's +10% growth.
Stocks Performance
XFOR vs S&P 500
Performance Gap
XFOR vs S&P 500
Performance By Year
XFOR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
X4 Pharmaceuticals Inc
Glance View
X4 Pharmaceuticals is a drug developer focused on rare immune disorders. Its main product is mavorixafor, an oral medicine sold in the U.S. as Xolremdi for WHIM syndrome, a genetic condition that leaves patients with too few white blood cells and frequent infections. The company’s work is centered on finding and bringing to market medicines that help patients whose immune systems do not work properly. The company makes money mainly by selling its approved medicine through the prescription-drug channel, where patients receive it through doctors and specialty pharmacies and payers help cover the cost. It may also earn money from partnerships or licensing around its drug programs. Its customers are patients, doctors, hospitals, and insurers that decide whether the medicine is covered and used. X4 sits in the biotech part of healthcare, where a company’s value depends on proving that a specific drug works, getting regulatory approval, and then turning that drug into steady prescriptions. That makes it different from a broad drugmaker: it is a focused, single-product style business built around one core medicine and a small pipeline aimed at niche diseases with limited treatment options.
